Neurotez Engages Invictus Global Capital as Corporate Finance & Capital Markets Advisors

Share Article

Neurotez is proud to announce the engagement of Invictus Global Capital, Inc. to serve as the Company's corporate finance & capital markets advisor to assist in reviewing strategic options to meet the Company’s growth objectives and enhance shareholder value.

News Image
As an early-stage biotechnology, Neurotez has been making exciting discoveries in the Alzheimer’s Disease space that not just address symptoms, but also provide therapeutic and curative solutions.

Neurotez is proud to announce the engagement of Invictus Global Capital, Inc. to serve as the Company's corporate finance & capital markets advisor to assist in reviewing strategic options to meet the Company’s growth objectives and enhance shareholder value.

“We are thrilled with Invictus’ global outreach as an independent adviser and management partner, matching our efforts to expand in the markets globally (see our GCA Therapeutics deal). This group will provide Neurotez support in our efforts to grow the company and we anticipate working immediately and closely moving forward efficiently”, said Nikolaos Tezapsidis, President & CEO of Neurotez.

President & Managing Partner of Invictus Global Capital, Philip Brooks, said “As an early-stage biotechnology, Neurotez has been making exciting discoveries in the Alzheimer’s Disease space that not just address symptoms, but also provide therapeutic and curative solutions. With more than 5 million patients in the US alone, this is something that could have a very positive impact on so many lives and in so many families. We are delighted to be assisting Neurotez in advancing their strategy for growth towards commercialization. In addition to providing Neurotez with counsel on capital formation and structuring, we provide management with strategic support including drug development advisory that will lead to maximizing shareholder value.”

About Invictus Global Capital, Inc.

Invictus Global Capital Inc. is an independent corporate finance and capital markets advisory firm with offices in the British Virgin Islands, Toronto, New York City, and Zurich. Invictus specializes in strategic advisory support for technology company public offerings, capital formation, mergers & acquisitions, and corporate strategy. Our principal relationships are with high growth, innovation driven companies across full technology verticals from around the world. Please contact info(at)invictusipos(dot)com.
http://www.invictusipos.com/

About Neurotez, Inc.

Neurotez, Inc. is a private Delaware corporation whose primary goal is to develop a recombinant human Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD) and as a preventative for those who are at risk. Their mission is to become world leaders in the advancement of AD therapy and prevention, utilizing an integrated platform from discovery to proof of concept clinical trials for CNS drugs that are both well tolerated and efficacious. The company sees several liquidity and exit options within the next few years. For investment inquires, please contact investorrelations(at)neurotez(dot)com
http://neurotez.com/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Investor Relations
Visit website